Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (924) 924
Publication (144) 144
Dissertation (25) 25
Conference Proceeding (20) 20
Book Chapter (18) 18
Book Review (6) 6
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (538) 538
index medicus (535) 535
gbm (524) 524
glioblastoma multiforme (508) 508
oncology (385) 385
glioblastoma (312) 312
cancer (256) 256
glioblastoma - pathology (240) 240
brain neoplasms - pathology (223) 223
male (211) 211
female (207) 207
clinical neurology (184) 184
glioma (184) 184
animals (165) 165
tumors (163) 163
cell line, tumor (162) 162
middle aged (153) 153
expression (149) 149
adult (138) 138
brain tumors (136) 136
glioblastoma - genetics (136) 136
temozolomide (134) 134
chemotherapy (133) 133
glioblastoma - metabolism (131) 131
survival (131) 131
gliomas (128) 128
glioblastoma - drug therapy (126) 126
brain neoplasms - metabolism (125) 125
analysis (121) 121
brain neoplasms - genetics (121) 121
aged (120) 120
prognosis (120) 120
brain cancer (114) 114
apoptosis (111) 111
brain neoplasms - drug therapy (110) 110
cell biology (107) 107
medicine & public health (107) 107
radiotherapy (106) 106
surgery (102) 102
article (97) 97
mice (96) 96
brain (86) 86
malignant glioma (86) 86
magnetic resonance imaging (83) 83
neurology (82) 82
care and treatment (79) 79
growth (76) 76
brain neoplasms - therapy (75) 75
multiforme (75) 75
biochemistry & molecular biology (73) 73
gene expression (72) 72
neurosciences (72) 72
brain-tumors (71) 71
brain neoplasms - mortality (69) 69
glioblastoma - therapy (69) 69
invasion (69) 69
research (67) 67
cells (66) 66
proliferation (66) 66
stem cells (66) 66
cell proliferation (64) 64
glioblastoma - mortality (64) 64
proteins (64) 64
malignant gliomas (62) 62
treatment outcome (61) 61
radiation (60) 60
glioblastoma-multiforme (59) 59
adjuvant temozolomide (58) 58
gene expression regulation, neoplastic (56) 56
patients (56) 56
survival analysis (56) 56
nervous system diseases (55) 55
medical prognosis (53) 53
glioma - pathology (52) 52
angiogenesis (51) 51
brain neoplasms - surgery (50) 50
immunotherapy (50) 50
activation (49) 49
development and progression (49) 49
radiology, nuclear medicine & medical imaging (49) 49
genetic aspects (47) 47
inhibition (47) 47
therapy (47) 47
stem-cells (46) 46
adolescent (45) 45
dacarbazine - analogs & derivatives (45) 45
glioblastoma - surgery (45) 45
health aspects (45) 45
immunohistochemistry (45) 45
in-vitro (45) 45
retrospective studies (45) 45
young adult (45) 45
cancer research (44) 44
medicine, research & experimental (44) 44
signal transduction (44) 44
xenograft model antitumor assays (44) 44
cell proliferation - drug effects (43) 43
research paper (43) 43
combined modality therapy (42) 42
review (42) 42
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (958) 958
Chinese (12) 12
Polish (2) 2
French (1) 1
Japanese (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Temozolomide resistance in glioblastoma multiforme
by Lee, Sang Y
Genes & Diseases, ISSN 2352-3042, 09/2016, Volume 3, Issue 3, pp. 198 - 210
Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do... 
Resistance | Temodar | Temozolomide | Adaptive | Intrinsic | Glioblastoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Emerging treatment strategies for glioblastoma multiforme
by Carlsson, Steven K and Brothers, Shaun P and Wahlestedt, Claes
EMBO Molecular Medicine, ISSN 1757-4676, 11/2014, Volume 6, Issue 11, pp. 1359 - 1370
Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5‐year mortality. GBM has a paltry median survival of 12.6 months... 
brain imaging | glioblastoma multiforme (GBM) | cancer stem cells | biomarkers | epigenetics | Biomarkers | Epigenetics | Brain imaging | Glioblastoma multiforme (GBM) | Cancer stem cells | MEDICINE, RESEARCH & EXPERIMENTAL | SMALL-MOLECULE | PROGNOSTIC VALUE | CANCER STEM-CELLS | TEMOZOLOMIDE | MALIGNANT GLIOMA | GROWTH-FACTOR RECEPTOR | 5-AMINOLEVULINIC ACID | GUIDED RESECTION | TUMOR-GROWTH | BRAIN | Glioblastoma - therapy | Immunotherapy - methods | Glioblastoma - diagnosis | Brain Neoplasms - diagnosis | Humans | Brain Neoplasms - therapy | Biomedical Research - trends | Care and treatment | Radiotherapy | Glioblastoma multiforme | Stem cells | Neuroimaging | Nuclear magnetic resonance--NMR | Brain tumors | Brain cancer | Glioblastoma | DNA methylation | Monoclonal antibodies | Radiation therapy | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Reactive Astrocytes in Glioblastoma Multiforme
by Guan, Xiudong and Hasan, Md Nabiul and Maniar, Shelly and Jia, Wang and Sun, Dandan
Molecular Neurobiology, ISSN 0893-7648, 8/2018, Volume 55, Issue 8, pp. 6927 - 6938
Despite the multidisciplinary integration in the therapeutic management of glioblastoma multiforme (GBM), the prognosis of GBM patients is poor. There is... 
Neurology | Neurosciences | Biomedicine | Cytokines | Glioblastoma multiforme (GBM) | Neurobiology | Ion transporters | Reactive astrocytes | Ion channels | Cell Biology | STEM-CELLS | CHLORIDE CHANNELS | POTASSIUM CHANNELS | INDUCED APOPTOSIS | ELEVATED GENE-1 | CA2+-ACTIVATED K+ CHANNEL | HUMAN GLIOMA-CELLS | NEUROSCIENCES | CALCIUM-CHANNELS | TUMOR-GROWTH | Glioblastoma - therapy | Animals | Cell Proliferation | Ion Channels - metabolism | Neoplasm Invasiveness | Glioblastoma - pathology | Humans | Astrocytes - pathology | Drug Resistance, Neoplasm | Medical colleges | Development and progression | Neural networks | Glioblastoma multiforme | Brain tumors | Stem cells | Cell survival | Calcium | Mesenchyme | Tumor cells | Astrocytes | Invasiveness | Glioblastoma | Blood-brain barrier | Medical prognosis | Glioma cells | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text CCL2/CCR2 signaling pathway in glioblastoma multiforme
by Vakilian, Alireza and Khorramdelazad, Hossein and Heidari, Parisa and Sheikh Rezaei, Zahra and Hassanshahi, Gholamhossein
Neurochemistry International, ISSN 0197-0186, 02/2017, Volume 103, pp. 1 - 7
Glioblastoma multiform (GBM) is described as one of the most frequent primary brain tumors. These types of malignancies constitute only 15% of all primary... 
CCL2 | MCP-1 | GBM | CC chemokine | Glioblastoma | BIOCHEMISTRY & MOLECULAR BIOLOGY | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | CXC CHEMOKINES | NEUROSCIENCES | GLIAL TUMORS | CROSS-TALK | CELL SUBSETS | TUMOR-ASSOCIATED MACROPHAGES | MOLECULAR-CLONING | GROWTH-FACTOR | CHEMOKINE RECEPTORS | GLIOMA-INFILTRATING MICROGLIA/MACROPHAGES | Receptors, CCR2 - metabolism | Animals | Signal Transduction - drug effects | Humans | Receptors, Chemokine - metabolism | Glioblastoma - metabolism | Signal Transduction - physiology | Chemokine CCL2 - metabolism | Brain Neoplasms - drug therapy | Brain Neoplasms - metabolism | Macrophages | Glioblastoma multiforme | Brain tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text PD-L1/PD-1 Axis in Glioblastoma Multiforme
by Litak, Jakub and Mazurek, Marek and Grochowski, Cezary and Kamieniak, Piotr and Roliński, Jacek
International Journal of Molecular Sciences, ISSN 1422-0067, 10/2019, Volume 20, Issue 21, p. 5347
Glioblastoma (GBM) is the most popular primary central nervous system cancer and has an extremely expansive course. Aggressive tumor growth correlates with... 
pd1 ligand | glioblastoma multiforme | gbm | pd1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Glioblastoma multiforme: a review of where we have been and where we are going
by Adamson, Cory and Kanu, Okezie O and Mehta, Ankit I and Di, Chunhui and Lin, Ningjing and Mattox, Austin K and Bigner, Darell D
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 08/2009, Volume 18, Issue 8, pp. 1061 - 1083
Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable... 
glioblastoma multiforme | signaling cascades | GBM | genetics | oncogenomics | Genetics | Oncogenomics | Glioblastoma multiforme | Signaling cascades | PRIMARY BRAIN-TUMORS | THERAPY-ONCOLOGY-GROUP | BEVACIZUMAB PLUS IRINOTECAN | PRIMARY INTRACRANIAL TUMORS | PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | RECURSIVE PARTITIONING ANALYSIS | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | HIGH-GRADE ASTROCYTOMA | COMPARATIVE GENOMIC HYBRIDIZATION | Humans | Central Nervous System Neoplasms - therapy | Treatment Outcome | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Central Nervous System Neoplasms - epidemiology | Radiotherapy | Glioblastoma - epidemiology | Glioblastoma - therapy | Neurosurgical Procedures | Central Nervous System Neoplasms - pathology | Clinical Trials, Phase III as Topic | Central Nervous System Neoplasms - immunology | Glioblastoma - immunology | Glioblastoma - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis
by Zhu, Vivian F and Yang, Jingxuan and LeBrun, Drake G and Li, Min
Cancer Letters, ISSN 0304-3835, 2011, Volume 316, Issue 2, pp. 139 - 150
Abstract Cytokines play a significant role in cancer diagnosis, prognosis and therapy. The immune system’s failure to recognize the malignant tumor cells and... 
Hematology, Oncology and Palliative Medicine | Glioblastoma Multiforme (GBM) | Therapy | Cytokine | T-CELL APOPTOSIS | MESSENGER-RNA EXPRESSION | NECROSIS-FACTOR-ALPHA | INTERLEUKIN-4-PSEUDOMONAS EXOTOXIN | BRAIN-TUMORS | RECURRENT MALIGNANT GLIOMA | INTERLEUKIN-6 EXPRESSION | INTERFERON-GAMMA | ONCOLOGY | BETA GENE-THERAPY | ENDOTHELIAL GROWTH-FACTOR | Animals | Brain Neoplasms - immunology | Glioblastoma - immunology | Signal Transduction | Glioblastoma - pathology | Humans | Brain Neoplasms - pathology | Tumor Necrosis Factor-alpha - immunology | Cytokines - immunology | Cytokines | Glioblastoma multiforme | Stem cells | Kinases | Brain cancer | Immune system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development
by Zhao, Hua-fu and Wang, Jing and Shao, Wei and Wu, Chang-peng and Chen, Zhong-ping and To, Shing-shun Tony and Li, Wei-ping
Molecular Cancer, ISSN 1476-4598, 06/2017, Volume 16, Issue 1, pp. 100 - 16
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system. One of the most widely used... 
GBM | PI3K | MTOR | Glioblastoma | ADVANCED SOLID TUMORS | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-II | KINASE INHIBITOR | VIVO ANTITUMOR-ACTIVITY | PI3K/MTOR INHIBITOR | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | I DOSE-ESCALATION | CELL LUNG-CANCER | ONCOLOGY | METASTATIC BREAST-CANCER | mTOR | CHRONIC LYMPHOCYTIC-LEUKEMIA | TOR Serine-Threonine Kinases - metabolism | Humans | Brain Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Brain Neoplasms - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Glioblastoma - metabolism | Brain Neoplasms - mortality | Catalysis | Drug Evaluation, Preclinical | Proto-Oncogene Proteins c-akt - metabolism | Isoenzymes | Treatment Outcome | Antineoplastic Agents - chemistry | Brain Neoplasms - drug therapy | Drug Discovery | Clinical Studies as Topic | Protein Kinase Inhibitors - administration & dosage | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glioblastoma - pathology | Glioblastoma - drug therapy | Glioblastoma - mortality | Care and treatment | Genetic aspects | Cellular signal transduction | Research | Glioblastoma multiforme | TOR protein | Drugs | Plasma | Phosphorylation | Prognosis | Motility | Brain cancer | Central nervous system | Clinical trials | AKT protein | Kinases | Phosphatase | Synergism | Alkylation | Proteins | Angiogenesis | Signal transduction | Cell growth | Epidermal growth factor | DNA methylation | Deoxyribonucleic acid--DNA | Medical research | Cell survival | Rapamycin | Metabolism | Patients | 1-Phosphatidylinositol 3-kinase | Inhibitors | Protein synthesis | Medical prognosis | Ligands | Solid tumors | Temozolomide | Mutation | Methylation | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme
by Karsy, Michael and Arslan, Erol and Moy, Fred
Genes and Cancer, ISSN 1947-6019, 01/2012, Volume 3, Issue 1, pp. 3 - 15
Glioblastoma multiforme (GBM) is an aggressive grade IV astrocytoma with a 1-year median survival rate despite current treatment modalities. A thorough... 
glioma | microarray | GBM | review | miR | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme
by Polivka, Jiri and Holubec, Lubos and Kubikova, Tereza and Priban, Vladimir and Hes, Ondrej and Pivovarcikova, Kristyna and Treskova, Inka
Anticancer Research, ISSN 0250-7005, 01/2017, Volume 37, Issue 1, pp. 21 - 33
Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor in adults with generally dismal prognosis, early clinical deterioration and... 
GBM | Targeted therapy | Immunotherapy | Clinical trials | PD1 inhibition | Immune checkpoint inhibitors | Review | Personalized medicine | Glioblastoma multiforme | CTLA4 inhibition | targeted therapy | NEWLY-DIAGNOSED GLIOBLASTOMA | INTEGRATED GENOMIC ANALYSIS | RECURRENT GLIOBLASTOMA | BEVACIZUMAB PLUS IRINOTECAN | OPEN-LABEL | immune checkpoint inhibitors | personalized medicine | RADIATION-THERAPY | CELL LUNG-CANCER | PHASE-II TRIAL | ONCOLOGY | review | immunotherapy | clinical trials | CENTRAL-NERVOUS-SYSTEM | HIGH-GRADE GLIOMAS | Humans | Antibodies, Monoclonal - adverse effects | Tumor Microenvironment | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Brain Neoplasms - metabolism | Brain Neoplasms - immunology | Molecular Targeted Therapy - trends | Glioblastoma - genetics | Antineoplastic Agents - adverse effects | Immunotherapy - trends | Angiogenesis Inhibitors - therapeutic use | Biomarkers, Tumor - metabolism | Glioblastoma - metabolism | Biomarkers, Tumor - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Brain Neoplasms - genetics | Treatment Outcome | Immunotherapy - adverse effects | Glioblastoma - therapy | Animals | Glioblastoma - immunology | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Brain Neoplasms - therapy | Biomarkers, Tumor - genetics | Biomarkers, Tumor - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pediatric multifocal glioblastoma multiforme with fulminant course
by Cugati, Goutham and Jain, Pradeep Kumar and Pande, Anil and Symss, Nigel Peter and Chakravarthy, Vasudevan and Ramamurthi, Ravi
Journal of Neurosciences in Rural Practice, ISSN 0976-3147, 05/2012, Volume 3, Issue 2, pp. 174 - 177
ABSTRACT Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor. GBM in children is less common than in adults and has a better... 
Case Report | recraniotomy | pediatric GBM | multicentric GBM | Multifocal GBM | Case studies | Care and treatment | Patient outcomes | Tumors in children | Diagnosis | Radiotherapy | Glioblastoma multiforme | Pediatrics | Postoperative period | Medical imaging | Radiation therapy | Tumors | Children & youth | Quality of life | pediatric gbm | multifocal gbm | multicentric gbm
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme
by Steven De Vleeschouwer and Steffen Fieuws and Stefan Rutkowski and Frank Van Calenbergh and Johannes Van Loon and Jan Goffin and Raf Sciot and Guido Wilms and Philippe Demaerel and Monika Warmuth-Metz and Niels Soerensen and Johannes E.A. Wolff and Sabine Wagner and Eckhart Kaempgen and Stefaan W. Van Gool
Clinical Cancer Research, ISSN 1078-0432, 05/2008, Volume 14, Issue 10, pp. 3098 - 3104
Purpose: To investigate the therapeutic role of adjuvant vaccination with autologous mature dendritic cells (DC) loaded with tumor lysates derived from... 
dendritic cells | high grade glioma | relapse | malignant glioma | immunotherapy | PHASE-III TRIAL | MALIGNANT GLIOMA | NERVOUS-SYSTEM | FUTURE-DIRECTIONS | ONCOLOGY | RECURRENT GLIOBLASTOMA | VACCINATION | HIGH-GRADE GLIOMAS | CHEMOTHERAPY | BRAIN-TUMORS | HIT-GBM | Antigens, Neoplasm - immunology | Dendritic Cells - immunology | Humans | Middle Aged | Neoplasm Recurrence, Local - therapy | Kaplan-Meier Estimate | Postoperative Period | Male | Neoplasm Recurrence, Local - mortality | Glioblastoma - therapy | Cancer Vaccines - immunology | Disease-Free Survival | Cancer Vaccines - therapeutic use | Antigens, Neoplasm - therapeutic use | Adolescent | Brain Neoplasms - therapy | Adult | Female | Aged | Child | Glioblastoma - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights